A

American Health Research | Clinical Research of Rock Hill

Research site
(Unclaimed)
Location
370 S. Herlong Avenue, Rock Hill, North Carolina, United States of America

Site insights

Top conditions

Top treatments

Treprostinil
Tiotropium Bromide
Empagliflozin
Astegolimab
BLU-5937
JZP-258
EMPagliflozin
Olorinab
Sacubitril
High-Sodium Oxybate

Parent organization

This site is a part of American Health Research

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 31 total trials

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-1)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling
Refractory Chronic Cough
Drug: BLU-5937
Drug: Placebo

HZNP-HZN-825-303 (HARBOR) comprises of 2 parts. Part 1 (Core Phase) is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial...

Active, not recruiting
Idiopathic Pulmonary Fibrosis
Drug: Placebo
Drug: HZN-825

This is a multicenter, randomized, placebo- and active-controlled, parallel-group, 24-week trial to investigate the efficacy, safety, and tolerabilit...

Enrolling
Heart Failure
Biological: XXB750 High Dose
Drug: Sacubitril/valsartan

This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Astegolimab

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function

Enrolling
Moderate to Severe Asthma
Drug: povorcitinib
Other: placebo

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: BMS-986278 Placebo
Drug: BMS-986278

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmo...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Astegolimab

This is an open-label, multicenter, single-group study designed to determine the effectiveness of Mucinex® when used by patients to treat SCB over a...

Enrolling
Chronic Bronchitis
Drug: Guafenesin tablets
Locations recently updated

The aim of this study is to quantify the change in blood pressure when participants with narcolepsy treated with high-sodium oxybate are transitioned...

Enrolling
Narcolepsy
Drug: JZP258
Locations recently updated

Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis.

Invitation-only
Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease
Device: Treprostinil Ultrasonic Nebulizer
Drug: Inhaled Treprostinil

Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FV...

Enrolling
Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease
Drug: Inhaled Treprostinil
Drug: Placebo

This is a pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR (Optimized Background Regimen) versus placebo + OBR in pati...

Active, not recruiting
MAC Lung Disease
Treatment Refractory MAC Lung Disease
Drug: Epetraborole
Drug: Placebo

Trial sponsors

Boehringer Ingelheim logo
Jazz Pharmaceuticals logo
Novartis logo
United Therapeutics logo
V
A
Aldeyra Therapeutics logo
Amgen logo
A
B

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems